Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancer. Academic Article uri icon

Overview

abstract

  • OBJECTIVES: We compare the Bard BTA (bladder tumor antigen) test to voided cytology studies in patients undergoing surveillance cystoscopy for recurrent bladder cancer. MATERIALS AND METHODS: A prospective, blinded, multicenter trial was performed. RESULTS: A total of 499 patients underwent 1,014 cystoscopic examinations and tumor was identified in 151. The bladder tumor antigen test was more sensitive than cytology studies in detecting recurrent cancer (p < 0.001), being positive in 61 cases versus 25 for cytology. The trial in healthy volunteers and nonurological patients estimates bladder tumor antigen test specificity to be 95.9%. CONCLUSIONS: The bladder tumor antigen test is a simple, rapid and inexpensive adjunct to cystoscopy, and the results are equivalent or superior to those of voided cytology as performed in this trial.

publication date

  • August 1, 1995

Research

keywords

  • Antigens, Neoplasm
  • Urinary Bladder Neoplasms
  • Urine

Identity

Scopus Document Identifier

  • 0029074615

Digital Object Identifier (DOI)

  • 10.1097/00005392-199508000-00013

PubMed ID

  • 7609102

Additional Document Info

volume

  • 154

issue

  • 2 Pt 1